HC Wainwright Trims Oculis (NASDAQ:OCS) Target Price to $28.00

Oculis (NASDAQ:OCS) had its price objective dropped by research analysts at HC Wainwright from $29.00 to $28.00 in a report issued on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 133.92% from the stock’s current price.

OCS has been the topic of several other research reports. Chardan Capital reissued a “buy” rating and set a $30.00 price target on shares of Oculis in a research report on Tuesday, March 19th. Wedbush reissued an “outperform” rating and set a $29.00 price target on shares of Oculis in a research report on Wednesday, March 6th. Finally, Robert W. Baird lowered their price target on shares of Oculis from $64.00 to $35.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 19th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $29.14.

Oculis Stock Performance

Shares of OCS opened at $11.97 on Wednesday. Oculis has a 52-week low of $9.05 and a 52-week high of $14.50. The company has a quick ratio of 5.29, a current ratio of 5.29 and a debt-to-equity ratio of 0.01. The firm’s fifty day moving average is $11.90 and its two-hundred day moving average is $11.22.

Oculis (NASDAQ:OCS) last announced its earnings results on Monday, March 18th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.04. The business had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.28 million. Equities analysts predict that Oculis will post -1.75 earnings per share for the current fiscal year.

Institutional Trading of Oculis

Institutional investors and hedge funds have recently bought and sold shares of the stock. Barclays PLC purchased a new stake in Oculis during the second quarter worth about $44,000. Wolverine Asset Management LLC purchased a new stake in Oculis during the third quarter worth about $77,000. Searle & CO. purchased a new stake in Oculis during the fourth quarter worth about $112,000. Compagnie Lombard Odier SCmA increased its stake in Oculis by 47.3% during the fourth quarter. Compagnie Lombard Odier SCmA now owns 95,750 shares of the company’s stock worth $1,053,000 after purchasing an additional 30,750 shares during the period. Finally, abrdn plc purchased a new stake in Oculis during the fourth quarter worth about $15,980,000. 22.30% of the stock is currently owned by hedge funds and other institutional investors.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.